5747-48-8

Basic information

• Product Name: N-Des[2-(2-hydroxyethoxy)ethyl] Quetiapine
• Synonyms: 11-(piperazin-1-yl)dibenzo[b,f][1,4]thiazepine;11-Piperazinodibenzo[b,f][1,4]thiazepine;N-Desalkylquetiapine;Norquetiapine;2-(Piperazin-1-yl)dithiazepin;11-(Piperazin-1-yl);11-(1-Piperazinyl)-dibenzo[b,f][1,4]thiazepine;N-Des[2-(2-hydroxyethoxy)ethyl] Quetiapine
• CAS NO: 5747-48-8
• Molecular Formula: C₁₇H₁₇N₃S
• Molecular Weight: 295.41
• Product Categories: Heterocycles;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 5747-48-8.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 465.2 °C at 760 mmHg
• Flash Point: 235.2 °C
• Appearance: Pale-Yellow Solid
• Density: 1.30
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 8.55±0.10(Predicted)
• CAS DataBase Reference: N-Des[2-(2-hydroxyethoxy)ethyl] Quetiapine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Des[2-(2-hydroxyethoxy)ethyl] Quetiapine(5747-48-8)
• EPA Substance Registry System: N-Des[2-(2-hydroxyethoxy)ethyl] Quetiapine(5747-48-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 5747-48-8(Hazardous Substances Data)

Usage

Chemical Properties

Pale-Yellow Solid

Uses

11-(Piperazin-1-yl)dibenzo[b,f][1,4]thiazepine is a metabolite of Quetiapine, a Benzothiazepine with mixed serotonin and dopamine receptor antagonistic properties used as an antipsychotic.

Upstream product

• 111974-69-7 Quetiapine 
• 13745-86-3 11-chloro-dibenzo[b,f][1,4]thiazepine 
• 3159-07-7 dibenzo[b,f][1,4]thiazepin-11-one 
• 111974-73-3 phenyl [2-(phenylsulphanyl)phenyl]carbamate 
• 1134-94-7 2-phenylsulfanyl-aniline 
• 4171-83-9 2-nitrophenyl phenyl sulfide 
• 88-73-3 2-Chloronitrobenzene 
• 108-98-5 thiophenol 
• 1217310-64-9 (E)-tert-butyl 4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazine-1-carboxylate 
• 110-85-0 piperazine 
• 1176987-11-3 C₁₃H₁₀N₂S*ClH 
• 111974-74-4 N-Dealkyl Quetiapine dihydrochloride 
• 546-68-9 titanium(IV) isopropylate 
• 753475-15-9 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine hydrochloride 

Downstream Products

• 111974-74-4 N-Dealkyl Quetiapine dihydrochloride 
• 753475-15-9 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine hydrochloride 
• 111974-69-7 Quetiapine 

Relevant articles and documents

Design, synthesis, and molecular docking study of new piperazine derivative as potential antimicrobial agents

Herein, we describe the successful design and synthesis of seventeen new 1,4-diazinanes, compounds commonly known as piperazines. This group of piperazine derivatives (3a-q) were fully characterized by 1H NMR, 13C NMR, FT-IR, and LCMS spectral techniques. The molecular structure of piperazine derivative (3h) was further established by single crystal X-ray diffraction analysis. All reported compounds were evaluated for their antibacterial and antifungal potential against five bacterial (Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa) and two fungal strains (Candida albicans and Cryptococcus neoformans). The complete bacterial screening results are provided. As documented, piperazine derivative 3e performed the best against these bacteria. Additionally, data obtained during molecular docking studies are very encouraging with respect to potential utilization of these compounds to help overcome microbe resistance to pharmaceutical drugs, as explicitly noted in this manuscript.

Design, synthesis and anticancer activity of N-(1-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl derivatives

Novel N-(1-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl derivatives were designed, synthesized and their chemical structures were confirmed by 1H NMR, 13C NMR and Mass spectra. The anticancer activities of the newly synthesized compounds were evaluated in vitro against three human cancer cell lines including K562, Colo-205 and MDA-MB 231 by MTT assay. The screening results showed that five compounds (16b, 16d, 16i, 16p and 16q) exhibited potent cytotoxic activities with IC50 values between 20 and 40 μM. Further in vitro studies revealed that inhibition of sirtuins could be the possible mechanism of action of these molecules.

DIBENZOTHIAZEPINE MODULATORS OF DOPAMINE, ALPHA ADRENERGIC, AND SEROTONIN RECEPTORS

The present invention relates to new dibenzothiazepine modulators of D1 receptors, D2 receptors, alpha-1 adrenergic receptors, alpha-2 adrenergic receptors, H1 receptors, 5-HT1A receptors, and/or 5-HT2 receptors, pharmaceutical compositions thereof, and methods of use thereof.